HIM
AZN icon

Hanlon Investment Management’s AstraZeneca AZN Stock Holding History

Hanlon Investment Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Sell
1,372
-60
-4% -$11.3K 0.14% 188
2026
Q1 		$282K Buy
1,432
+307
+27% +$59.2K 0.16% 180
2025
Q4 		$207K Buy
+1,125
New +$197K 0.11% 197

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Hanlon Investment Management's AZN Position: Q2 2026 in Review

Hanlon Investment Management reduced its AstraZeneca (AZN) stake by 4.2% in Q2 2026, selling an estimated $11.3K and leaving 1,372 shares worth $260K. The position accounts for 0.14% of the portfolio, ranked #188.

Hanlon Investment Management first reported a position in AZN in Q4 2025 and has held it in 3 quarters since. The position peaked at $282K in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Hanlon Investment Management held 1,372 shares of AstraZeneca worth $260K as of Q2 2026.
  • Hanlon Investment Management sold 60 AstraZeneca shares in Q2 2026, an estimated $11.3K.
  • AstraZeneca made up 0.14% of Hanlon Investment Management's portfolio in Q2 2026, its #188 holding.
  • Hanlon Investment Management first reported a position in AstraZeneca in Q4 2025 and has held it in 3 quarters since.
  • Hanlon Investment Management's AstraZeneca position peaked at $282K in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Hanlon Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.